Morgan Advanced Materials (MGAM)

Sector:

Electronic and Electrical Equipment

Index:

FTSE 250

229.50p
   
  • Change Today:
      3.00p
  • 52 Week High: 341.50p
  • 52 Week Low: 177.40p
  • Currency: UK Pounds
  • Shares Issued: 279.55m
  • Volume: 328,680
  • Market Cap: £641.57m
  • Beta: 0.01

Broker tips: Spirax-Sarco Engineering, Morgan Advanced Materials, Dr Martens

By Michele Maatouk

Date: Friday 14 Jul 2023

LONDON (ShareCast) - (Sharecast News) - UBS upgraded Spirax-Sarco Engineering on Friday to 'buy' from 'neutral' and lifted the price target to 12,400p from 11,560p, citing an attractive entry point.
"We now see the shares as presenting an attractive entry point, having de-risked our FY23e estimates and updated our views on the drivers of growth ahead of IP from next year," it said.

"We note near-term risk/reward is now better balanced, following share price weakness in Q2 (-15% underperformance versus defensive peer Halma)."

UBS added that while consensus has been coming down recently, the shares are not reacting to downgrades.

It said the stock's valuation is as attractive now as it was at the Covid trough in March 2020 on an EV/ EBIT basis.

"On a price-to-earnings basis shares are near the 15-year average, representing even better value, for a group that can grow revenues organically at mid single digit+ through cycle (outperforming trade-weighted IP by 4x on our analysis) maintaining sector-leading margins and compounding earnings growth at double-digits (12% compound annual growth rate in our model)."

Elsewhere, Barclays initiated coverage of Morgan Advanced Materials with an 'overweight' rating and 365p price target.

"We think improving end-market exposure will drive higher through-cycle growth for MGAM, with the group EBITA margin expanding to mid-teens and a new peak," it said.

The bank noted that focused M&A is on the agenda, but said it also sees scope for a supportive capital return, while longer term further portfolio rationalisation could drive multiple expansion.

Bank of America Merrill Lynch upgraded Dr Martens to 'buy', arguing that the iconic bootmaker has an "attractive value proposition".

The bank noted that Dr Martens shares have de-rated by 25% since the IPO.

"We see opportunity to consider the stock given its more robust earnings expectations and signs of a cleaner equity story to come," it said.

BofA ML said the shares are "simply too cheap" and that four profit warnings in the last 12 months and a recent downgrade to medium-term guidance suggest expectations have reset.

The bank pointed out that changes are on their way. "The group is reinvesting in the business, which should help limit operational surprises, while senior personnel changes are also taking place," it said.

BofA also noted that the brand isn't broken and that its popularity has actually improved.

In addition, it forecast return on capital employed above peers.

BofA cut its price target on the stock to 165p from 210p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

MGAM Market Data

Currency UK Pounds
Share Price 229.50p
Change Today 3.00p
% Change 1.32 %
52 Week High 341.50p
52 Week Low 177.40p
Volume 328,680
Shares Issued 279.55m
Market Cap £641.57m
Beta 0.01

MGAM Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
30.10% above the market average30.10% above the market average30.10% above the market average30.10% above the market average30.10% above the market average
82.86% above the sector average82.86% above the sector average82.86% above the sector average82.86% above the sector average82.86% above the sector average
Price Trend
60.05% below the market average60.05% below the market average60.05% below the market average60.05% below the market average60.05% below the market average
31.43% below the sector average31.43% below the sector average31.43% below the sector average31.43% below the sector average31.43% below the sector average
Income
87.05% above the market average87.05% above the market average87.05% above the market average87.05% above the market average87.05% above the market average
87.50% above the sector average87.50% above the sector average87.50% above the sector average87.50% above the sector average87.50% above the sector average
Growth
65.91% below the market average65.91% below the market average65.91% below the market average65.91% below the market average65.91% below the market average
57.58% below the sector average57.58% below the sector average57.58% below the sector average57.58% below the sector average57.58% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 4
Sell 0
Strong Sell 0
Total 10
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

MGAM Dividends

  Latest Previous
  Final Interim
Ex-Div 10-Apr-25 24-Oct-24
Paid 13-May-25 15-Nov-24
Amount 6.80p 5.40p

Trades for 18-Jul-2025

Time Volume / Share Price
15:02 48 @ 231.00p
16:35 93,631 @ 229.50p
16:35 96 @ 229.50p
16:35 27 @ 229.50p
16:35 1,844 @ 229.50p

MGAM Key Personnel

CFO Richard Armitage
CEO Damien Caby

Top of Page